Citi raises Krystal Biotech price target to $386
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz raised the price target on Krystal Biotech (NASDAQ: KRYS) to $386 from $378, while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
